Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effects Study of GST-HG171/Ritonavir in Healthy Chinese Participants
NCT06084507Phase 1Unknown
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atilotrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Status: unknown.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06084507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084507.